ARTICLE | Company News
Genmab, Immatics in bispecific immunotherapy deal
July 12, 2018 9:01 PM UTC
Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications.
Immatics will receive $54 million up front and is eligible for $550 million in milestones for each product the partners develop, plus royalties up to double digits. Genmab may opt to add two additional targets...